EBS today
$6.04-$0.01 (-0.17%)close Nov 11, 2026Trend
DailyDowntrend (confirmed)
4 hourExpanding
1 hourStrong Bullish
15 minLeaning Bullish
5 minStrong Bullish
Daily trend turns up above $7.70
Key levels
Resistance$7.30
Resistance$6.60
Support$6.04
Support$5.51
Latest news & SEC filings
DealEmergent BioSolutions wins $22.3 million modification for its anthrax shot
All EBS news →About Emergent BioSolutions
Emergent BioSolutions is a life sciences company that develops and manufactures medical countermeasures against public health threats such as anthrax, smallpox, mpox, Ebola, and botulism, along with naloxone nasal sprays for opioid overdose. It sells these products primarily to U.S. and international government agencies, as well as to pharmacies, health departments, and community organizations. The company also provides contract development and manufacturing services to pharmaceutical and government customers.
Based on the company's 10-K filed Feb 27, 2026.
NYSE · Healthcare
Emergent BioSolutions Inc. (EBS)
What Is the Price Target for EBS?
SEPT Low Target
$10.00
SEPT Mid Target
$10.00
SEPT High Target
$10.00
Analyst Consensus
$10.00
Is EBS a Buy or Sell Right Now?
Thesis
- •Revenue growing -28.8% YoY with DECLINING trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for EBS.
Start Free Trial →Is EBS Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/E Forward, P/B, Analyst Consensus
Fair Value
$10.53
6
Moat Score
NONE
6/9
Piotroski Score
1.4
Altman Z-Score
What Is Smart Money Doing with EBS?
Insider Signal
SELLING
0 buys / 9 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| DeGolyer Donald W | director | Sale | 17,800 | $126K | Oct 7, 2026 |
| Williams Paul Anthony | officer | Sale | 3,000 | $20K | Oct 1, 2026 |
| Hartzel William | officer | Sale | 1,741 | $14K | Jun 8, 2026 |
| Williams Paul Anthony | officer | Sale | 694 | $6K | Jun 8, 2026 |
| Glessner Coleen | officer | Sale | 2,018 | $16K | Jun 8, 2026 |
| LINDAHL RICHARD S | officer | Sale | 3,964 | $32K | Jun 8, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →EBS Growth Story
Revenue YoY
-28.8%
3yr Revenue CAGR
-12.7%
EPS Growth YoY
125.83%
FCF Growth YoY
338.0%
Revenue Trend
DECLINING
Dark Pool Trades for EBS
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for EBS, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:00:30 | $6.04 | 1,600 | $$10K | SELL |
| 21:00:29 | $6.04 | 4,832 | $$29K | SELL |
| 21:00:29 | $6.04 | 4,777 | $$29K | SELL |
| 20:56:10 | $6.04 | 1,087 | $$7K | BUY |
| 20:42:15 | $6.05 | 1,000 | $$6K | SELL |
5 dark pool trades shown · $$80K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Emergent BioSolutions Inc. (EBS) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →EBS — frequently asked questions
What is EBS stock price today?
Emergent BioSolutions Inc. (EBS) is at $6.04, down 0.17% (-$0.01) at the Nov 11, 2026 close.
Why is EBS stock moving today?
Latest EBS news — Nov 5, 2026: Emergent BioSolutions wins $22.3 million modification for its anthrax shot
What is the EBS price target?
The average analyst price target for EBS is $10.00, ranging from $10 to $10, based on 2 analysts.
What do analysts rate EBS?
Analyst ratings for EBS: 0 Buy, 2 Hold, 1 Sell — consensus Hold.
Did EBS beat earnings?
EBS last reported on Nov 2, 2026: EPS -$0.36 vs -$0.39 expected — a beat of 8.0%.
Does EBS pay a dividend?
EBS does not currently pay a dividend.
How much debt does EBS have?
Emergent BioSolutions Inc. reported $590M of debt and $140M of cash (Jun 30, 2026).
What are EBS support and resistance levels?
Support: $6.04, $5.51, $5.04. Resistance: $6.60, $7.30, $8.01.
What are insiders doing with EBS?
Insider activity: SELLING, 0 buys and 9 sells in the last 90 days.
What is the latest news on EBS?
Nov 5, 2026: Emergent BioSolutions wins $22.3 million modification for its anthrax shot